Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb dose ranging study of Psilocybin

Trial Profile

A phase IIb dose ranging study of Psilocybin

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs Psilocybin (Primary)
  • Indications Depressive disorders
  • Focus Therapeutic Use
  • Sponsors COMPASS Pathways
  • Most Recent Events

    • 06 Sep 2018 New trial record
    • 22 Aug 2018 According to a COMPASS Pathways media release, the company has received approval from the US Food and Drug Administration (FDA) for a clinical trial in psilocybin therapy for treatment-resistant depression. Regulatory approvals for the trial have already been given in the UK, the Netherlands and Canada. The trial will begin in the UK later this month and sites in other countries will join the trial as further regulatory approvals are received.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top